Expired Canadian patentCanada
Taxane derivatives for targeted therapy of cancer
CA 2362937 C · Owner: The Uab Research Foundation · Inventors: Safavy, Ahmad
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention describes for the first time the design and synthesis of a soluble tumor-directed paclitaxel prodrug which may establish a new mode of utilization of the taxane class of anticancer agents in cancer therapy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 23, 2000 and granted March 22, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 23, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 23, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledFebruary 23, 2000
GrantedMarch 22, 2011
Term endedFebruary 23, 2020
Patent numberCA 2362937 C
Classification (IPC)A61K38/00 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.